Drugs / LPCN 1021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03868059 | Apr 2018 → Feb 2019 | hypogonadism, male | Lipocine Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPCN 1021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03868059 ↗ |